S

Sanofi

Global pharma company; vaccines and R&D

Head of Taiwan CSU - Clinical Study Units

Full-TimeUpdated on 10/22/2026Deadline 10/30/26
No salary listed
Expert
Master's, PharmD, PhD, MD
Taipei City, Taiwan
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • An advanced degree in Life Sciences, Medicine, Pharmacy, or a related scientific discipline (MSc, MD, PharmD, or PhD).
  • At least 10 years of clinical research experience, including at least 3 years of people management experience.
  • Strong knowledge of clinical development, ICH-GCP, and global and local clinical trial regulations.
  • Strong clinical development and Medical Affairs expertise.
  • Strategic thinking and business acumen to align clinical operations with organizational priorities.
  • Leadership, change management, stakeholder engagement, and coaching skills.
  • Risk management, problem-solving, and decision-making capabilities.
  • A data-driven mindset and experience using analytics and digital tools.
  • Project and vendor management capabilities.
  • Commitment to ethics, quality, and patient-centricity.
  • Written and verbal communication skills in English and the local language.
Responsibilities
  • Lead the Country Clinical Study Unit to deliver clinical studies with quality, efficiency, and compliance with ICH-GCP, regulatory requirements, and company standards.
  • Drive operational excellence through continuous improvement, lessons learned, digital innovation, and quality-by-design approaches.
  • Optimize study portfolio execution through resource planning, site strategy, recruitment forecasting, risk management, budget oversight, and performance monitoring.
  • Build and maintain networks with investigators, hospitals, and key opinion leaders to support current and future clinical programs.
  • Ensure country readiness through effective governance, quality oversight, and inspection preparedness.
  • Provide strategic input to global and regional teams on study planning, protocol optimization, feasibility, and clinical development strategies.
  • Develop and execute the long-term Clinical Study Unit strategy aligned with research and development, Global Medical Affairs, and Clinical Study Operations priorities.
  • Use clinical intelligence, Real-World Data, analytics, and digital capabilities to improve study planning, productivity, and innovation.
  • Monitor healthcare trends, regulatory changes, and the competitive landscape to strengthen local clinical capabilities.
  • Partner with Medical Affairs and cross-functional teams, including Regulatory, Finance, Procurement, Legal, Compliance, Human Resources, and Pharmacovigilance, to support clinical development objectives.
  • Drive key opinion leader and investigator engagement, study communication, and Clinical Study Unit visibility within the affiliate.
  • Represent the company in relevant industry forums and strengthen relationships with clinical research partners.
  • Lead country clinical operations, including resource planning, site selection, feasibility assessment, study milestones, and operational performance.
  • Ensure timely communication of study progress, risks, and insights across local, regional, and global stakeholders.
  • Oversee local requirements, including documentation, regulatory submissions, contracts, translations, and vendor activities.
  • Promote a strong culture of quality, compliance, and Health, Safety & Environment.
  • Lead, coach, and develop the Clinical Study Unit team through recruitment, capability building, performance management, and succession planning.
  • Manage Clinical Study Unit budgets, resource allocation, forecasting, and cost optimization in partnership with regional leadership.
  • Foster accountability, collaboration, and continuous learning across the organization.
  • Provide strategic oversight of functional service providers and local vendors to ensure quality, compliance, and effective clinical study delivery.
  • Monitor vendor performance, risks, capacity, and service delivery against agreed timelines, budgets, and key performance indicators.
  • Partner with Procurement and regional teams on vendor selection, implementation, and governance.
Desired Qualifications
  • Experience in Regulatory Affairs, Market Access, Medical Affairs, or external vendor management.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...